Fig. 4From: UCHL1 contributes to insensitivity to endocrine therapy in triple-negative breast cancer by deubiquitinating and stabilizing KLF5Correlation analysis of UCHL1 promoter CpG site methylation levels and gene expression in breast cancer tissues. (A) Comparison of UCHL1 expression in normal breast tissue (GTEx-B), TCGA breast cancer (TCGA-BRCA) subtypes, and adjacent cancer tissues (T adj.). (B) A heatmap (top) showing the correlation between UCHL1 expression and UCHL1 DNA methylation levels in corresponding tissues in TCGA-BRCA subtypes. The black box marks 7 methylation sites related to the promoter region. A bar chart (bottom) comparing UCHL1 DNA CpG site methylation levels in TCGA-BRCA subtypes. The black box marks 7 methylation sites related to the promoter region. (C) Correlation analysis of methylation levels of 7 methylation sites related to the promoter region and UCHL1 expression levels. (D) A UMP plot chart showing the single cells from breast cancer tissues, color-coded by UCHL1 expression (left) and their associated cell type cluster (right). (E) A scatter plot illustrates the expression of UCHL1 in various molecular subtypes of breast cancer and circulating tumor cells. The data is from a recent single-cell sequencing dataset [3], from: https://singlecell.broadinstitute.org/single_cell/study/SCP1039/a-single-cell-and-spatially-resolved-atlas-of-human-breast-cancers. (F) qRT-PCR was used to detect the expression of UCHL1 in MCF-7, BT-474, MDA-MB-468, and SUM149 cells. G-H.UCHL expression in MCF-7 and MDA-MB-468 cells after treatment with the methylation reagent 5-Aza-Dc at the mRNA (G) and protein (H) levels in MCF-7 and MDA-MB-468 cells. ***, pā<ā0.001Back to article page